Paratek Pharmaceuticals to Present at Two August 2020 Healthcare Conferences
August 05 2020 - 4:01PM
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage
biopharmaceutical company focused on the development and
commercialization of novel life-saving therapies for
life-threatening diseases or other public health threats for
civilian, government and military use, today announced that the
Company will present at two upcoming healthcare conferences.
The BTIG Biotechnology Conference 2020 Tuesday,
August 11, 2020 at 11:30 a.m. ET.To access the live webcast of
Paratek's presentation, please
visit https://wsw.com/webcast/btig/prtk/.
2020 Wedbush PacGrow Healthcare Virtual
ConferenceWednesday, August 12, 2020 at 2:55 p.m. ET.To
access the live webcast of Paratek's presentation, please visit
https://wsw.com/webcast/wedbush36/prtk/2262299.
Please connect to the sites at least 15 minutes prior to the
live presentations to ensure adequate time for any software
downloads that may be necessary to listen to the webcast. A replay
of the webcast can be accessed for up to 90 days following the live
presentation.
About Paratek Pharmaceuticals, Inc.Paratek
Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical
company focused on the development and commercialization of novel
life-saving therapies for life-threatening diseases or other public
health threats for civilian, government and military use.
The Company’s lead commercial product, NUZYRA® (omadacycline),
is a once-daily oral and intravenous antibiotic available in the
U.S. for the treatment of adults with community-acquired bacterial
pneumonia and acute bacterial skin and skin structure infections.
Paratek has a collaboration agreement with Zai Lab for the
development and commercialization of omadacycline in the greater
China region and retains all remaining global rights.
Paratek exclusively licensed U.S. rights and rights to the
greater China territory for SEYSARA® (sarecycline), a once-daily
oral therapy for the treatment of moderate to severe acne vulgaris,
to Almirall, LLC (Almirall). Paratek retains the development and
commercialization rights for sarecycline in the rest of the
world.
In 2019, Paratek was awarded a contract from BARDA to support
the development of NUZYRA for the treatment of pulmonary
anthrax.
For more information, visit www.ParatekPharma.com or follow
@ParatekPharma on Twitter.
Forward Looking Statements This press release
contains forward-looking statements including statements related to
our overall strategy, products, prospects and potential. All
statements, other than statements of historical facts, included in
this press release are forward-looking statements, and are
identified by words such as "advancing," "expect," "look forward,"
"anticipate," "continue," and other words and terms of similar
meaning. These forward-looking statements are based upon our
current expectations and involve substantial risks and
uncertainties. We may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in our
forward-looking statements and you should not place undue reliance
on these forward-looking statements. Our actual results and the
timing of events could differ materially from those included in
such forward-looking statements as a result of these risks and
uncertainties. These and other risk factors are discussed under
"Risk Factors" and elsewhere in our Annual Report on Form 10-K for
the year ended December 31, 2019 and our other filings with the
Securities and Exchange Commission. We expressly disclaim any
obligation or undertaking to update or revise any forward-looking
statements contained herein.
CONTACT: Investor and Media
Relations: Ben Strain 617-807-6688
ir@ParatekPharma.com
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2024 to May 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From May 2023 to May 2024